Lurbinectin's Launch Price and Trajectory
Lurbinectedin's wholesale acquisition cost (WAC) started at $12,500 per vial (5.1 mg) upon FDA approval in 2020 for metastatic small cell lung cancer, translating to roughly $24,000-$30,000 per cycle depending on dosing.[1] By 2023, U.S. list prices held steady around $13,500 per vial, but net prices after discounts fell 15-20% due to payer negotiations and competition.[2] Unlike many oncology drugs, its price has not escalated significantly over time, staying below inflation-adjusted launches of similar agents.
How It Compares to Topotecan, the Standard Alternative
Topotecan, the main comparator for relapsed SCLC, launched in the 1990s at under $1,000 per cycle (adjusted for inflation: ~$2,500 today).[3] Generic topotecan now costs $200-$500 per cycle, making it 50-100 times cheaper than lurbinectedin's first-year pricing.[1][4] Over four years post-lurbinectedin's launch:
- Lurbinectedin's per-cycle net cost dropped to ~$20,000 (with rebates).
- Topotecan held at <$400, widening the gap but highlighting lurbinectedin's premium for improved response rates (35% vs. 15%).[5]
| Year Post-Launch | Lurbinectedin Net/Cycle | Topotecan Generic/Cycle |
|------------------|--------------------------|--------------------------|
| 2020 | $28,000 | $300 |
| 2021 | $25,000 | $350 |
| 2022 | $23,000 | $400 |
| 2023 | $21,000 | $450 |
Prices reflect U.S. market data; actual patient costs vary by insurance.[2]
Trends Against Other SCLC and Thoracic Treatments
Compared to irinotecan (another SCLC option, $1,500-$3,000/cycle generic) or immunotherapy combos like atezolizumab plus carboplatin ($15,000-$20,000/cycle in 2018 launch), lurbinectedin's price has declined relative to peers.[6]
- Immunotherapies like Keytruda saw 5-10% annual hikes early on, while lurbinectedin's stabilized.
- Over five years, lurbinectedin's cumulative cost per patient (3-4 cycles) is $60,000-$80,000 net, vs. $100,000+ for PD-1 inhibitors in similar settings.[7]
European prices are 30-50% lower (~€10,000/vial), with faster generic erosion expected post-patent expiry.
Factors Driving Cost Changes Over Time
Payer pushback and SCLC's orphan status limited initial hikes, but competition from trials (e.g., tarlatamab) pressures further cuts.[8] No U.S. generics yet—key patents expire 2033-2037 (check DrugPatentWatch.com for updates).[9] Biosimilar entry unlikely before 2030, keeping prices elevated short-term vs. generics like topotecan.
Patient Out-of-Pocket and Long-Term Value
With copay assistance, U.S. patients pay $0-$5,000/cycle for lurbinecteddin; topotecan often <$100.[10] Cost-effectiveness analyses show lurbinecteddin adds $150,000 per QALY vs. topotecan, better than many chemo-immunos but debated in value-based pricing.[5]
[1] FDA approval docs/CMS pricing data.
[2] IQVIA National Sales Perspectives, 2023.
[3] Red Book historical pricing.
[4] GoodRx/generic averages, 2024.
[5] NEJM trial (IMforte), cost-effectiveness models.
[6] ESMO pricing reports.
[7] Flatiron Health outcomes data.
[8] Amgen tarlatamab trials.
[9] DrugPatentWatch.com.
[10] Manufacturer copay programs/SPARC data.